A little over a year ago, Medtronic brought in a complete outsider to reinvigorate a company whose biggest divisions were slowing down.
Omar Ishrak is known for having engineered a small miracle at GE when Jack Welch installed him to run the ultrasound division in the company. Ishrak transformed the business — a business that in Welch’s words had some “false starts” — into a billion-dollar operation thereby catapulting himself into the topmost ranks of the company. And the world, including Medtronic’s board of directors, noticed.
On July 11, an executive who follows Ishrak tweeted the following:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Today, Ishrak responded to Altraif’s tweet like this:
It might take a while to bring about such a major turnaround at the world’s largest medical device company. Yet, Ishrak can take heart in the fact that, at least from a vision perspective, Medtronic appears to be headed the right way.
